LA JOLLA, Calif., May 20 /PRNewswire/ -- Aragon Pharmaceuticals today announced it has raised $8 million in Series A financing led by The Column Group and OrbiMed Advisors. Funds from the Series A financing will be used to discover and develop new small molecule therapeutics for the treatment of hormone-resistant cancers, with an initial focus on prostate and breast cancer.
Aragon Pharmaceuticals is a San Diego-based biopharmaceutical company built on the pioneering research of Charles Sawyers, M.D., an investigator at Memorial Sloan Kettering Cancer Center and the Howard Hughes Medical Institute, and Michael Jung, Ph.D., a professor at
Aragon is bringing together a proven team to drive the drug discovery programs. The Company is led by Richard A. Heyman, Ph.D., President and Head of Research and Development, who has worked in the nuclear receptor drug discovery field for 20 years and brought multiple compounds into the clinic and market. Aragon's Board of Directors includes Richard Heyman, Peter Svennilson, Founder and Managing Partner of The Column Group and Carl Gordon, founding General Partner of OrbiMed.
Rick Klausner, Aragon's Co-Chairman of the Scientific Advisory Board, Managing Partner at The Column Group, and former Director of the National Cancer Institute, stated that "30% of all cancers arise from hormone responsive tissues and hormonal therapy has been one of the bedrocks of cancer treatment. Unfortunately most of these tumors are or become resistant to available therapies. Breakthrough science has created the opportunity for Aragon to solve the problem of treatment resistance by creating a new approach to hormone receptor therapy."
"Aragon will build off the work of our founders and focus on the discovery and development of compounds that target the degradation of the androgen and estrogen receptor, to treat patients with hormone refractory disease," stated Dr. Richard Heyman. "The company has recruited an experienced drug discovery team and several world-renowned scientists to the Scientific Advisory Board to help guide the discovery and development of our research programs."
Peter Svennilson noted, "It is the caliber of the people behind Aragon and the tremendous potential that this approach has for treating hormone dependent cancers that excited us about funding this opportunity. The Aragon team is poised to generate a pipeline of novel cancer therapies and I look forward to working with Aragon to achieve their vision to effectively treat hormone refractory cancers."
For more information, please see:
|SOURCE Aragon Pharmaceuticals|
Copyright©2009 PR Newswire.
All rights reserved